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Abstract
HARGRAVE, KIMBERLY M., CHANGLONG LI,
BRETT J. MEYER, STEPHEN D. KACHMAN, DIANE L.
HARTZELL, MARY ANNE DELLA-FERA, JESS L.
MINER, AND CLIFTON A. BAILE. Adipose depletion
and apoptosis induced by trans-10, cis-12 conjugated
linoleic acid in mice. Obes Res. 2002;10:1284–1290.
Objective: To compare the effectiveness of a conjugated
linoleic acid (CLA) isomer mixture (mCLA) with each main
isomer [trans-10,cis-12 CLA (CLA10,12) and cis-9,trans-11
CLA (CLA9,11)] in causing body lipid loss and adipose
tissue apoptosis.
Research Methods and Procedures: Mice selected over 16
generations for high (MH) or low (ML) energy expenditure
and a control group (MC) were fed diets containing either
soy oil or soy oil plus mCLA, CLA10,12, or CLA9,11 for 5
days in one study and 14 days in a second study.
Results: Mice fed mCLA or CLA10,12 had less body lipid
(p  0.05), smaller retroperitoneal fat pads (p  0.05), and
ate less (p  0.01) than mice fed no CLA or CLA9,11 for
5 days. Mice consuming 1% mCLA or 0.5% CLA10,12
gained less weight (p  0.01) and had less body lipid
(p  0.05) and smaller epididymal (p  0.05) and ret-
roperitoneal fat pads (p  0.01) than mice consuming
either control or 0.5% CLA9,11-containing diets for 14
days. Only mCLA and CLA10,12 increased apoptosis in
retroperitoneal fat pads (p  0.01). The effects of mCLA
and CLA10,12 were independent of genetic line except
for the effect on adipocyte apoptosis. Mice of the MH
line were slightly less sensitive than MC or ML mice to
CLA-induced adipose tissue apoptosis.
Discussion: CLA10,12, but not CLA9,11, can induce both
body fat loss and adipose apoptosis. Although mice of a
genotype with less body fat and greater metabolic rate and
feed intake appear less sensitive, these CLA effects are
robust for mice of varying metabolic background.
Key words: mouse, conjugated linoleic acid, apoptosis,
body fat
Introduction
Conjugated linoleic acid (CLA), a group of positional and
geometric isomers of linoleic acid, has received consider-
able attention recently because of its potential health bene-
fits. In addition to anticarcinogenic (1,2), antiatherogenic
(3,4), and antidiabetic effects (5,6), dietary CLA can induce
body-fat loss in multiple species (7–10). Body-fat depletion
is fairly specific in that body protein is spared or even
increased (11). Although the mechanism for CLA’s effect
on body fat is not yet defined, we and others have shown
that it is associated with apoptosis of adipocytes (12–14).
Commercial preparations of CLA are composed mainly
of cis-9, trans-11 CLA (CLA9,11) and trans-10, cis-12 CLA
(CLA10,12). Many of CLA’s effects seem to be isomer
specific. In cultured 3T3-L1 adipocytes, CLA10,12 de-
creased lipoprotein lipase activity and intracellular triacyl-
glycerol and glycerol content and increased glycerol re-
lease. In contrast, CLA9,11 had no effect (15). Based on
these findings, Park et al. (15) proposed that CLA10,12 was
the isomer that alters body composition.
Our goal was to test this hypothesis directly by supple-
menting the diet of mice with either CLA10,12 or CLA9,11.
In addition, we were interested in whether the effectiveness
of CLA in altering body composition would depend on
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genetic background. To this end, we studied the responses
to CLA of mice selected over 16 generations for high meta-
bolic rate/heat loss (MH) or low metabolic rate (ML), and
control mice from the same outbred background that were
not developed by selection on metabolic rate (MC) (16).
Research Methods and Procedures
Animals
We used mice from lines that had been developed by
genetic selection on energy expenditure (16). The original
population had equal contributions of Harlan Sprague-Daw-
ley ICR and National Institutes of Health strains, and
Charles River CF-1 and CFW(Sw) strains. Lines were de-
veloped by applying selection pressure to males of the base
population for high energy expenditure (MH), low energy
expenditure (ML), or no selection (MC) over 16 genera-
tions. MH mice exhibit 50% greater energy expenditure,
consume 23% more feed, and are 30% leaner than the ML
mice (16,17). For the present study, mice from each line
were housed individually at 22 °C under a photoperiod of 12
hours light and 12 hours dark. All mice were fed AIN-93G
for 1 week before experiments. Procedures were approved
by the University of Nebraska Institutional Animal Care and
Use Committee.
Materials
Purified (99%) CLA10,12 and CLA9,11, and mixed CLA
(mCLA) (18) were purchased from Nu-Check-Prep (Ely-
sian, MN). The mCLA used in Trial 2 was kindly provided
by BASF (BASF Nutrition Research; MEM/BD Neumuehle
13D-76,877 Offenbach). The CLA treatments were mixed
into a purified base diet (AIN-93G) by Dyets, Inc. (Bethle-
hem, PA). Soy oil was replaced with CLA (1:1 wt/wt),
depending on treatments listed below. All diets contained
7% total fat.
Trial 1: Effect of Dietary mCLA, CLA9,11, and
CLA10,12 on Body Weight, Body Lipid, and
Feed Intake
Male and female mice (12 weeks old) were blocked by
sex and line, and within blocks were randomly assigned to
five diets (N  72):
1. control diet (AIN-93G) containing 7% soy oil (n  18)
2. control diet pair-fed to treatment group 3 (n  18)
3. diet containing 2% mCLA (1.8% conjugated isomers,
0.44% CLA10,12, 41% CLA9,11; n  12)
4. diet containing 0.88% CLA10,12 (same concentration of
CLA10,12 as diet 3; n  12)
5. diet containing 0.82% CLA9,11 (same concentration of
CLA9,11 as diet 3; n  12)
Feed intake was measured as disappearance from glass
jars equipped with a cylindrical stainless steel screen at-
tached to a small-holed lid. Spillage of powdered feed
occurs only rarely from these jars. Feed intake and body
weights were measured daily for 5 days. On day 6, mice
were killed by CO2 asphyxia, and retroperitoneal fat pads
were removed and weighed. The carcasses (less retroperi-
toneal fat) were freeze-dried and extracted with ether to
determine percentage of body lipid.
Trial 2: Effect of Dietary mCLA, CLA9,11, and
CLA10,12 on Body Weight, Body Lipid, Feed Intake,
and Apoptosis in Adipose Tissue of Mice Selected for
High and Low Metabolic Rate
Male mice (12 weeks old) were assigned to the following
treatments (n  18 per treatment):
1. control diet (AIN-93G) containing 7% soy oil
2. mCLA (1.0% total conjugated isomers)
3. 0.5% CLA10,12
4. 0.5% CLA9,11
Feed intake and body weights were measured weekly for
2 weeks. On day 15, mice were killed by CO2 asphyxia.
Blood was collected by cardiac puncture and immediately
analyzed for glucose concentration by a SureStep glucose
monitor (Lifescan, Milpitas, CA). Percentage of body lipid
and lean mass were determined by DXA (PixiMus, Madi-
son, WI). Liver and retroperitoneal and epididymal fat pads
were removed and weighed. Retroperitoneal fat pads were
frozen at 80 °C until assay.
Apoptosis Assay
Apoptosis was determined by assay of internucleosomal
DNA degradation. Genomic DNA was isolated using DNA-
zol (Molecular Research Center, Inc., Cincinnati, OH) with
minor modification to the manufacturer’s protocol. Retro-
peritoneal fat (100 mg) was minced in 1 mL of DNAzol and
10 L of polyacryl carrier (Molecular Research Center,
Inc.). After digestion with 0.1 mg/mL proteinase K and
centrifugation, the supernatant was transferred to a new tube
and DNA was precipitated with ethanol. Tissue DNA (300
ng/500 L TE buffer) was loaded onto a 100K Nanosep
spin column (Gelman Laboratory, Ann Arbor, MI), centri-
fuged at 5000g for 10 minutes, and washed with 100 L TE.
Eluate and retained DNA were quantified using PicoGreen
(Molecular Probes, Inc., Eugene, OR). Apoptosis was quan-
tified as the ratio of eluate (fragmented DNA) to total DNA.
Data Analyses
For each trial, the General Linear Models procedure of
SAS was used to compute ANOVA. In Trial 1, main effects
of treatment, sex, and genetic line were included in analy-
ses, and significance of interactions was determined. Anal-
yses for Trial 2 were similar but included no sex effect.
When main effects were significant, the least significant
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difference test was used for mean separation. Probability
0.05 was considered significant.
Results
Trial 1: Feed Intake, Body Weight, Body Lipid, and
Retroperitoneal Fat Pad Weight in Mice Fed mCLA,
CLA9,11, or CLA10,12 for 5 Days
Feed intake was reduced by both mCLA and CLA10,12
consumption (Figure 1 ; p  0.01). Feed intake by mice
consuming CLA9,11 was essentially the same as control.
The reduction in intake caused by mCLA and CLA10,12
was not observed after 1 full day of consumption, but was
clearly established after 2 days of consumption (diet  day
interaction, p  0.05). What seems to be an increase in feed
intake on day 5 is a consequence of this period being 28
hours rather than 24 hours. This technical factor did not
influence intake of the pair-fed mice because their limited
feed allowance was generally consumed in 24 hours.
As expected, mice of the high metabolic rate background
(MH) consumed 22% more feed (p  0.01; Table 1) than
the control background (MC), which consumed 13% more
(p  0.01) than the low metabolic rate genotype (ML).
Body weight at the experiment’s conclusion did not differ
between these genetic lines. Males were 22% heavier than
females (p  0.01), but did not consume more feed. We
detected no significant interaction of either sex or line with
treatment diet or day.
Compared with control, percentage of body lipid was
reduced by 20% in mice fed mCLA and CLA10,12, but not
in either pair-fed mice or those fed CLA9,11 (p  0.05;
Table 2). Similarly, retroperitoneal fat pad weight was less
in the mCLA and CLA10,12 groups than in mice fed
CLA9,11 (p  0.05). Fat pad weight of mice fed CLA9,11
was similar to control. Although the genetic lines of mice
differed (p 0.01) in body lipid content and retroperitoneal
fat pad weight, there were no interactions of line or sex with
treatment (Table 2).
Trial 2: Feed Intake, Body Weight, Body Lipid, and
Apoptosis in Adipose of Mice Fed mCLA, CLA9,11,
or CLA10,12
Feed intake during the 2-week trial was 4.76, 4.17, 4.33,
and 4.81 g/d, for mice fed the control, mCLA, CLA10,12,
and CLA9,11 diets, respectively (SEM 0.147). Consump-
tion was less in both the mCLA and CLA10,12 treatments
than in either the control or CLA9,11 treatments (p 0.05).
None of the treatments affected body weight (Table 3).
However, body-weight gain was reduced by dietary CLA
(p  0.05). There was no genetic line  diet interaction for
either feed intake or body weight.
The mCLA and CLA10,12 diets reduced percentage of
body lipid compared with both control and CLA9,11 (p 
0.05; Table 3). Similarly, both epididymal and retroperito-
neal fat pad weights were decreased (p  0.01) by mCLA
and CLA10,12 compared with control and CLA9,11 (Figure
2). Lean body mass was not affected by either diet or line.
The effects of genetic line on body lipid were essentially the
same as observed in Trial 1 (data not shown). There was no
line  treatment interaction.
There was no significant treatment effect on serum glu-
cose, but there was a significant line effect (p  0.01). MH
Figure 1: Feed intake of 12-week-old mice (n  12 to 18/
treatment) fed control diet (ad libitum), control diet (pair-fed to
mCLA group), 2% mCLA, 0.88% CLA10,12, or 0.82% CLA9,11
for 5 days (Trial 1). Means with different letters differ (p  0.01).
Error bars represent SEM. CLA, conjugated linoleic acid.
Table 1. Effects of line and sex on feed intake and
body weight in Trial 1
Line Mean  SE Sex Mean  SE
Feed Intake (g/d)
MH 4.4 0.1x M 3.8 0.1
MC 3.6 0.1y F 3.6  0.1
ML 3.2 0.1z
Body Weight (g)
MH 33.4 0.7 M 36.8 0.6x
MC 34.0 0.7 F 30.2 0.6y
ML 33.2 0.7
xyz Means with different superscripts differ ( p  0.01).
MH, MC, and ML are lines developed by genetic selection for
high, control, and low metabolic rate, respectively.
Two-way interactions involving line, diet, sex, or day were not
significant.
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mice had greater (p  0.01) serum glucose concentration
(224 mg/dL; SEM  12) compared with MC (173 mg/dL)
and ML (142 mg/dL) mice.
Liver weight was affected by treatment (p  0.05), but
there was no difference between control (1.55 g; SEM 
0.05) and any of the CLA treatments (mCLA, 1.70 g;
CLA10,12, 1.53 g; CLA9,11, 1.45 g). Liver weight of
CLA9,11-fed mice was less (p  0.05) than that of mCLA-
and CLA10,12-fed mice.
There were significant treatment (p 0.01), line (p 0.01),
and treatment line (p 0.05) effects on DNA fragmentation
(apoptosis) in retroperitoneal fat pads (Figure 3). In MC and
ML genetic lines, apoptosis was markedly increased by mCLA
and CLA10,12 (p  0.01), but not by CLA9,11. In MH
mice, both mCLA and CLA10,12 increased apoptosis com-
pared with CLA9,11 (p  0.05), but the effects of mCLA
and CLA10,12 compared with control did not meet the 5%
standard of significance (0.05  p  0.10).
Table 2. Main effects of line and sex on RP fat pad weight and percent body fat in mice fed control diet or diets
containing CLA for 5 days (Trial 1)
Treatment Mean  SE Line Mean  SE Sex Mean  SE
RP fat pad weight (g)
Control 0.24 0.02abxy MH 0.17 0.02a M 0.27 0.02x
Pair Fed 0.22 0.02ax MC 0.28 0.02b F 0.17 0.02y
mCLA 0.16 0.03bx ML 0.21 0.02a
CLA10,12 0.19 0.03bxy
CLA9,11 0.28 0.03ay
Percent body lipid
Control 14.8 0.9ab MH 11.6 0.8ax M 12.4 0.7x
Pair Fed 14.4 0.9a MC 14.2 0.8bxy F 15.3 0.7y
mCLA 11.8 1.0c ML 15.8 0.8by
CLA10,12 12.0 1.0bc
CLA9,11 16.1 1.0a
a,b,c Means with different superscripts differ ( p  0.05).
xy Means with different superscripts differ ( p  0.01).
MH, MC, and ML are lines developed by genetic selection for high, control, and low metabolic rate, respectively.
Two-way interactions involving line, diet, or day were not significant.
RP, retroperitoneal; CLA, conjugated linoleic acid.
Table 3. Feed intake, gain, and percentage of body lipid (Mean  SE) in mice consuming control diet or diets
containing mCLA, CLA10,12 or CLA9,11 (Trial 2)
Diet
Feed intake (g/d) Weight gain (g/d) Percentage
of body
lipidWeek 1 Week 2 Week 1 Week 2
Control 4.89 0.02a 5.03  0.25a 0.21 0.03ax 0.19 0.03x 22.2 0.9x
1% mCLA 4.02 0.25b 4.08  0.25b 0.03 0.03by 0.003 0.03y 17 0.9y
0.5% CLA10,12 4.39 0.25a 4.37  0.25a 0.06 0.03by 0.02 0.03y 14.5 0.9y
0.5% CLA9,11 5.01 0.25a 4.96  0.25a 0.11 0.03bx 0.22 0.03x 21.3 0.9x
a,b Means with different superscripts differ ( p  0.05).
xyz Means with different superscripts differ ( p  0.01).
Diet  genetic line interaction was not significant.
CLA, conjugated linoleic acid.
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Discussion
This work supports previous reports that dietary CLA can
decrease body fat and cause adipocyte apoptosis. Three
novel findings of this work are that: 1) the trans-10, cis-12
CLA isomer can produce these effects as well as the often-
used CLA mixture, 2) the cis-9, trans-11 CLA isomer does
not produce either of these effects, and 3) the body fat-
depleting effects of CLA are essentially the same in three
lines of mice, which differ significantly in baseline meta-
bolic rate, voluntary feed intake, and body composition.
Consumption of CLA10,12 for as little as 5 days caused
a 20% depletion of body fat. The mechanism of this effect
probably is not overly dependent on reduced feed intake.
Although CLA did cause mice to eat less, the pair-fed group
Figure 2: Effects of diet (n 18/treatment) and genetic line (n 24/line) on retroperitoneal fat pad (A) and epididymal fat pad (B) weights
of 12-week-old male mice selected for high (MH) or low (ML) metabolic rate or unselected (MC) and fed a control diet, 1% mCLA, 0.5%
CLA10,12, or 0.5% CLA9,11 for 14 days (Trial 2). a,bMeans with different letters differ (p  0.05). x,yMeans with different letters differ
(p  0.01). Error bars represent SEM. CLA, conjugated linoleic acid.
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in Trial 1 did not experience a reduction in body fat relative
to the ad libitum-fed control group. That the feed intake
reduction caused by CLA10,12 did not occur until the
second day of CLA consumption may be evidence that CLA
does not affect feed taste but rather influences a mechanism
that requires time for metabolism of this molecule or accu-
mulation of some critical concentration.
There seems to be a number of mechanisms involved in
CLA-induced reduction in body fat. CLA mixtures and
CLA10,12 have been shown to inhibit proliferation and
reduce triglyceride content in 3T3-L1 cells (12,19).
CLA10,12 reduced uptake of lipid by inhibiting the activi-
ties of lipoprotein lipase (20) and stearoyl-CoA desaturase
(21) in 3T3-L1 cells. A loss of adipocytes by apoptosis is
also responsible for the decreased body-fat content induced
by dietary CLA. CLA mixtures increased adipocyte apopto-
sis in mice (13,14), and CLA10,12 was shown to increase
apoptosis of 3T3-L1 cells in vitro (12).
The potential mechanisms involved in CLA-induced adi-
pocyte apoptosis have been investigated by Tsuboyama-
Kasaoka et al. (13), who found increased levels of tumor
necrosis factor alpha (TNF) and uncoupling protein-2
mRNA in white adipose tissue of mice fed CLA-containing
diets. TNF has been shown to induce adipocyte apoptosis
in vitro (22); however, the mechanism by which CLA
causes increased TNF levels is not known. CLA has been
shown to alter the type and amount of cellular fatty acids in
3T3-L1 cells; in particular, arachidonic acid content was
reduced more than 50% (23). Arachidonic acid is a precur-
sor to prostaglandins that act as ligands for peroxisome
proliferator activated receptor-gamma, which activates
genes important in adipogenesis. In fact, Brodie et al. (24)
found reduced levels of peroxisome proliferator activated
receptor-gamma in 3T3-L1 cells treated with CLA, and
Evans et al. (12) showed that CLA supplementation reduced
growth of preconfluent 3T3-L1 cells. Thus, CLA may in-
terfere with normal cellular mechanisms involved in pre-
adipocyte maturation. Susceptibility to apoptosis is higher
in immature adipocytes (25); thus, CLA may act by increas-
ing the proportion of cells that are susceptible to other
factors that trigger apoptosis.
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Figure 3: Trial 2: apoptosis in retroperitoneal fat pads of 12-week-old male mice (n  18/treatment) fed a control diet, 1% mCLA, 0.5%
CLA10,12, or 0.5% CLA9,11 for 14 days. a,bMeans with different letters differ (p  0.05). x,yMeans with different letters differ (p  0.01).
MC, MH, and ML represent genetic lines that were unselected or selected for high or low metabolic rate, respectively. Error bars represent
SEM. CLA, conjugated linoleic acid.
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